CohBar, Inc. (CWBR) News

CohBar, Inc. (CWBR): $0.21

0.02 (+8.12%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CWBR to Watchlist
Sign Up

Industry: Biotech


Ranked

of 474

in industry

Filter CWBR News Items

CWBR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest CWBR News From Around the Web

Below are the latest news stories about CohBar Inc that investors may wish to consider to help them evaluate CWBR as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, trader!

William White on InvestorPlace | February 3, 2022

Tri-Star Advisors Inc. Buys iShares TIPS Bond ETF, iShares Fallen Angels USD Bond ETF, BTC ...

Investment company Tri-Star Advisors Inc. (Current Portfolio) buys iShares TIPS Bond ETF, iShares Fallen Angels USD Bond ETF, BTC iShares MSCI USA Min Vol Factor ETF, BTC iShares Core MSCI EAFE ETF, iShares Agency Bond ETF, sells iShares 1-3 Year Credit Bond ETF, iShares Global Financials ETF, iShares Global Tech ETF, Vanguard S&P 500 ETF, Realty Income Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Tri-Star Advisors Inc..

Yahoo | January 13, 2022

CohBar to Present at H.C. Wainwright BIOCONNECT Conference

MENLO PARK, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the H.C. Wainwright BIOCONNECT Conference, being held virtually January 10 - 14, 2022. H.C. Wainwright

Yahoo | January 3, 2022

7 of the Best Penny Stocks Under $3 for 2022 to Buy Now

Penny stocks under $3 are full of potential and potential pitfalls.

Alex Sirois on InvestorPlace | December 31, 2021

CohBar, Inc. (NASDAQ:CWBR) Expected to Post Earnings of -$0.04 Per Share

Equities analysts expect CohBar, Inc. (NASDAQ:CWBR) to announce ($0.04) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for CohBars earnings. CohBar reported earnings per share of ($0.08) in the same quarter last year, which suggests a positive year-over-year growth rate of 50%. The company is []

Dakota Financial News | December 19, 2021

CohBar announces changes to board of directors, resignation of CSO

No summary available.

Seeking Alpha | December 17, 2021

CohBar Announces Changes to its Board of Directors and R&D Leadership

Founding board members transition to reconstituted Scientific Advisory Board

Intrado Digital Media | December 17, 2021

CohBar, Inc. (NASDAQ:CWBR) Short Interest Down 73.6% in November

CohBar, Inc. (NASDAQ:CWBR) saw a significant drop in short interest in November. As of November 15th, there was short interest totalling 880,400 shares, a drop of 73.6% from the October 31st total of 3,330,000 shares. Based on an average daily trading volume, of 1,790,000 shares, the short-interest ratio is presently 0.5 days. Shares of NASDAQ:CWBR []

Transcript Daily | November 30, 2021

CohBars CEO to Participate in Upcoming BIO Webinar

MENLO PARK, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced its Chief Executive Officer, Joseph Sarret, MD, JD, will be a participant on the BIO webinar titled Leveraging JPM Week to Achieve Business Development Goals on December 2, 2021 at 1:00pm ET. Registration is complimentary at https://bio-org.zoom.us/webinar/register/WN_j3I6XMIXRQSuf1d2wdoWjw .

Intrado Digital Media | November 29, 2021

CohBar’s CEO to Participate in Upcoming BIO Webinar

MENLO PARK, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced its Chief Executive Officer, Joseph Sarret, MD, JD, will be a participant on the BIO webinar titled “Leveraging JPM Week to Achieve Business Development Goals” on December 2, 2021 at 1:00pm ET. Registration is complimentary at https://bio-org.zoom.us/webinar/regis

Yahoo | November 29, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6046 seconds.